Home
VBI Vaccines

三月 2026的VBI Vaccines市场份额分析

Variation Biotechnologies Inc., also known as VBI Vaccines Inc., is a biopharmaceutical company, headquartered in Cambridge, Massachusetts, with research facilities in Ottawa, Ontario, Canada, and a research and manufacturing site in Rehovot, Israel.

健康 > 生物科技及制药

域vbivaccines.com

成立年份2001

员工51 - 200

年营收< $1M

VBI Vaccines

VBI Vaccines（包含公司地区分支机构）

vbivaccines.com

查看更多网站流量和参与度信息

VBI Vaccines热门域名的总访问量

了解VBI Vaccines市场份额和潜在市场覆盖范围。

过去 3 个月的总访问量

子公司明细

vbivaccines.com5.9K

使用销售情报查看更多信息

VBI Vaccines热门域名的平均访问时长

分析VBI Vaccines参与度指标。

过去 3 个月的平均访问时长

子公司明细

vbivaccines.com00:01:33

使用销售情报查看更多信息

VBI Vaccines热门域名的平均页面浏览量

了解VBI Vaccines如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。

过去 3 个月的平均页面浏览量

子公司明细

vbivaccines.com2.01

使用销售情报查看更多信息

VBI Vaccines 排名靠前的竞争对手（按域名）

三月 2026的热门相似网站，按亲和力排名

dynavax.com公司名称Dynavax Technologies员工201 - 500总部美国, 加利福尼亚, Emeryville年营收$200M - $500M总访问量7.6K健康 > 生物科技及制药

VBI Vaccines 采用的主要技术

这些是排名前 VBI Vaccines 的顶级域名所使用的网站技术（按行业分列）

付费广告 (4)

Google Adsense

视听媒体 (4)

YouTube

内容管理系统 (3)

WordPress

转化和分析 (3)

Google Analytics

更多技术

9

查看全部

VBI Vaccines 的新闻与信号

借助 Similarweb 销售信号提醒，每当在目标受众之中出现新的机会或威胁时，您都会收到所识别出购买信号的每日更新。

新闻VBI Vaccines Inc. launched interim tumor response data on May 29th '24.CAMBRIDGE, Mass.-(BUSINESS WIRE)-VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company's immunotherapeutic cancer vaccine candidate, in recurrent glioblastoma (rGBM) patients.

新闻VBI Vaccines Inc. received financing of $2.5M on Jun 30th '24.VBI received $2.5 million of consideration upon signing of definitive documents and is expected to receive up to an additional $30.5 million of consideration, subject to achievement of certain activities, with a target completion date of June 30, 2024.

新闻VBI Vaccines Inc. launched PreHevbri on Jul 22nd '23.Recently, Brii Bio executed two strategic transactions with VBI Vaccines Inc. (Nasdaq: VBIV), gaining exclusive global rights to BRII-179 and introducing PreHevbri®, a clinically differentiated prophylactic hepatitis B vaccine, to APAC countries and regions.